Search - tctmd.com

Displaying 81 - 100 of 504

Sort: Relevancy | Date

News Conference News AHA 2024

Spironolactone No Help for the Heart After Acute MI: CLEAR SYNERGY

Shelley Wood

November 17, 2024

News Conference News AHA 2024

Audits and Feedback Aid Pharmacist-Driven HF Care: PHARM-HF A&F

Michael O'Riordan

November 16, 2024

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

News Features

GDMT Uptake Remains Dismal in HFrEF: What’s the Right Fix?

Todd Neale

November 13, 2024

News Opinion CV Team Dispatch

October 2024 Dispatch for the CV Team

L.A. McKeown

October 25, 2024

News Daily News

Heart Failure and Cancer: HFSA Statement Explores the Interplay

Caitlin E. Cox

October 24, 2024

News Daily News

AHA Statement Outlines Cardiac Contributions to Brain Health

L.A. McKeown

October 11, 2024

News Conference News EACTS 2024

Will Semaglutide Change Cardiac Surgery? It Already Has

Yael L. Maxwell

October 10, 2024

News Daily News

Low CV Risk With ‘Living’ Cancer Therapies, Meta-analysis Shows

L.A. McKeown

October 09, 2024

News Conference News HFSA 2024

Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM

L.A. McKeown

October 04, 2024

News Conference News HFSA 2024

‘Metabolic Accelerator’ Cuts Weight, Not Muscle in HFpEF: HuMAIN-HF

Michael O'Riordan

October 03, 2024

News Conference News HFSA 2024

‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM

L.A. McKeown

October 02, 2024

News Conference News HFSA 2024

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

Michael O'Riordan

October 02, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2024

Shelley Wood

October 01, 2024

News Daily News

HFSA Stats 2024 a ‘Call to Action’ Against Rising Tide of HF

L.A. McKeown

October 01, 2024

News Conference News HFSA 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

Todd Neale

October 01, 2024

News Daily News

CVD Risk Twofold Higher in Patients With Cancer: ASPREE

Michael O'Riordan

September 27, 2024

News Daily News

HFSA Cancels Annual Meeting Due to Looming Hurricane

L.A. McKeown

September 26, 2024

News Daily News

Yes, Clinical Inertia IS the Leading Cause of GDMT Underuse in HFrEF

Todd Neale

September 20, 2024

News Daily News

Subcutaneous Furosemide Enables HF Patients to Address Congestion at Home

Caitlin E. Cox

September 16, 2024

Advertisement

Spironolactone No Help for the Heart After Acute MI: CLEAR SYNERGY

Audits and Feedback Aid Pharmacist-Driven HF Care: PHARM-HF A&F

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

GDMT Uptake Remains Dismal in HFrEF: What’s the Right Fix?

October 2024 Dispatch for the CV Team

Heart Failure and Cancer: HFSA Statement Explores the Interplay

AHA Statement Outlines Cardiac Contributions to Brain Health

Will Semaglutide Change Cardiac Surgery? It Already Has

Low CV Risk With ‘Living’ Cancer Therapies, Meta-analysis Shows

Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM

‘Metabolic Accelerator’ Cuts Weight, Not Muscle in HFpEF: HuMAIN-HF

‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

TCTMD’s Top 10 Most Popular Stories for September 2024

HFSA Stats 2024 a ‘Call to Action’ Against Rising Tide of HF

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

CVD Risk Twofold Higher in Patients With Cancer: ASPREE

HFSA Cancels Annual Meeting Due to Looming Hurricane

Yes, Clinical Inertia IS the Leading Cause of GDMT Underuse in HFrEF

Subcutaneous Furosemide Enables HF Patients to Address Congestion at Home

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content